Esperion Therapeutics, Inc.
NASDAQ:ESPRBiotechnology
+$0.00 today
- Market cap
- $661.15M
- Beta
- 1.07
- P/E (TTM)
- -107.3
- EPS (TTM)
- -$0.03
Volume 0.00M
Average 12.29M
ESPR Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Esperion Therapeutics, Inc.NASDAQ: ESPR
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin widens to 56.8%
Gross margin was 56.8% in Q1 FY2026, up 5.4 pp from a year earlier. On a trailing-twelve-month basis it was 65.0%, down 0.3 pp year over year. Over 3 fiscal years it widened by 3.7 pp.
Context
- Gross margin widened in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 67.9%
- Year-over-year change
- -11.4pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 67.9% | -11.4pp |
| FY2024 | 2024-12-31 | 79.4% | +16.5pp |
| FY2023 | 2023-12-31 | 62.8% | -1.5pp |
| FY2022 | 2022-12-31 | 64.3% | -17.6pp |
| FY2021 | 2021-12-31 | 81.9% | — |
Gross Margin vs competitors
How ESPR compares with its peers on the latest reported figures
- ESPR's LTM Mar 2026 gross margin of 65.0% is the 3rd highest of the 8 companies compared; the peer median is 44.4%.
- Its year-over-year change of -0.3 pp is the 4th highest of 8, against a peer median of -4.9 pp.
- Over three fiscal years its change of +3.7 pp compares with a peer median of +4.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 69.0% | +1.9 pp | -6.1 pp | |
| LTM Mar 2026 | 65.4% | -11.2 pp | -22.0 pp | |
| LTM Mar 2026 | 65.0% | -0.3 pp | +3.7 pp | |
| LTM Mar 2026 | 63.5% | -4.9 pp | +2.1 pp | |
| LTM Mar 2026 | 44.4% | +8.0 pp | +4.9 pp | |
| LTM Mar 2026 | 27.2% | +0.6 pp | +7.6 pp | |
| LTM Mar 2026 | -0.1% | -76.7 pp | +36.5 pp | |
| LTM Mar 2026 | -1316.9% | -337.8 pp | +605.7 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ESPR) | 44.4% | -4.9 pp | +4.9 pp | |
Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 78.45M | 75.48M | 116.33M | 332.31M | 403.14M |
| Cost of Revenue | 14.22M | 26.97M | 43.27M | 68.6M | 129.22M |
| Gross Profit | 64.23M | 48.51M | 73.07M | 263.71M | 273.91M |
| Gross Margin | 81.9% | 64.3% | 62.8% | 79.4% | 67.9% |
| Research & Development | 105.98M | 118.93M | 86.11M | 46.24M | 47.85M |
| Selling, General & Admin | 184.99M | 109.08M | 142.52M | 163.07M | 165.79M |
| Operating Expenses | 290.96M | 228.01M | 228.63M | 209.31M | 213.64M |
| Depreciation & Amortization | 612K | 500K | 164K | 63K | 105K |
| EBITDA | (222.14M) | (176.35M) | (150.11M) | 7.57M | 63.87M |
| EBITDA Margin | -283.2% | -233.7% | -129.0% | 2.3% | 15.8% |
| Operating Income | (226.73M) | (179.5M) | (155.56M) | 54.4M | 60.27M |
| Operating Margin | -289.0% | -237.8% | -133.7% | 16.4% | 15.0% |
| Interest Income | 0 | 0 | 0 | 0 | 3.5M |
| Interest Expense | 46.35M | 56.81M | 58.98M | 59.25M | 84.6M |
| Other Income / Expenses | (42.38M) | (54.16M) | (53.69M) | (106.15M) | (81.11M) |
| Income Before Tax | (269.11M) | (233.66M) | (209.25M) | (51.75M) | (20.84M) |
| Pre-Tax Margin | -343.0% | -309.6% | -179.9% | -15.6% | -5.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 1.84M |
| Net Income | (269.11M) | (233.66M) | (209.25M) | (51.75M) | (22.68M) |
| Net Margin | -343.0% | -309.6% | -179.9% | -15.6% | -5.6% |
| EPS (Basic) | (11.03) | (4.33) | (2.03) | (0.28) | (0.11) |
| EPS (Diluted) | (11.03) | (4.33) | (2.03) | (0.28) | (0.11) |
| Weighted Avg Shares | 28.9M | 66.41M | 103.11M | 187.18M | 207.87M |
| Weighted Avg Shares (Diluted) | 28.9M | 66.41M | 103.11M | 187.18M | 207.87M |
Esperion Therapeutics, Inc.
NASDAQ:ESPR
Intrinsic Alpha fair value
Locked
Current Price
$3.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.